The pituitary gland is the body’s master gland of the endocrine glands. Although it is a small organ, many types of tumors can develop within it. The recently revised fifth edition of the World Health Organization (WHO) classifications (2021 World Health Organization Classification of Central Nervous System Tumors and 2022 World Health Organization Classification of Endocrine and Neuroendocrine Tumors) revealed significant changes to the classification of pituitary adenomas, the most common type of pituitary gland tumor. This change categorized pituitary adenomas as neuroendocrine tumors and proposed the name to be revised to pituitary neuroendocrine tumor (PitNET). The International Classification of Diseases for Oncology behavior code for this tumor was previously “0” for benign tumor. In contrast, the fifth edition WHO classification has changed this code to “3” for primary malignant tumors as same to neuroendocrine tumor in other organs. Because the WHO classification made an important and significant change in the fundamental concept of the disease, in this paper, we will discuss the imaging diagnosis (magnetic resonance imaging, computed tomography, and positron emission tomography) of PitNET/pituitary adenoma in detail, considering these revisions as per the latest version of the WHO classification.
A deep learning–based model generated cerebral angiograms free from clinically significant misregistration that were equivalent to or better than digital subtraction angiograms both quantitatively ... Background Digital subtraction angiography (DSA) generates an image by subtracting a mask image from a dynamic angiogram. However, patient movement–caused misregistration artifacts can result in un...
9 July 2023 in Journal of Magnetic Resonance Imaging
Background: Although brain activities in Alzheimer's disease (AD) might be evaluated MRI and PET, the relationships between brain temperature (BT), the index of diffusivity along the perivascular space (ALPS index), and amyloid deposition in the cerebral cortex are still unclear.Purpose: To investigate the relationship between metabolic imaging measurements and clinical information in patients with AD and normal controls (NCs).Study Type: Retrospective analysis of a prospective dataset.Population: 58 participants (78.3 ± 6.8 years; 30 female): 29 AD patients and 29 age‐ and sex‐matched NCs from the Open Access Series of Imaging Studies dataset.Field Strength/Sequence: 3T; T1‐weighted magnetization‐prepared rapid gradient‐echo, diffusion tensor imaging with 64 directions, and dynamic 18F‐florbetapir PET.Assessment: Imaging metrics were compared between AD and NCs. These included BT calculated by the diffusivity of the lateral ventricles, ALPS index that reflects the glymphatic system, the mean standardized uptake value ratio (SUVR) of amyloid PET in the cerebral cortex and clinical information, such as age, sex, and MMSE.Statistical Tests: Pearson's or Spearman's correlation and multiple linear regression analyses. P values <0.05 were defined as statistically significant.Results: Significant positive correlations were found between BT and ALPS index (r = 0.44 for NCs), while significant negative correlations were found between age and ALPS index (rs = −0.43 for AD and − 0.47 for NCs). The SUVR of amyloid PET was not significantly associated with BT (P = 0.81 for AD and 0.21 for NCs) or ALPS index (P = 0.10 for AD and 0.52 for NCs). In the multiple regression analysis, age was significantly associated with BT, while age, sex, and presence of AD were significantly associated with the ALPS index.Data Conclusion: Impairment of the glymphatic system measured using MRI was associated with lower BT and aging.Level of Evidence: 3Technical Efficacy Stage: 1